PCSK9 LDL Cholesterol Regulation
Created for Biopharmaceutical Client
This medical animation explores the role of low density lipoprotein cholesterol (LDL-C) in atherosclerotic cardiovascular disease via regulation of LDL-C levels in the liver. By contrasting the LDL-C processing with and without PCSK9, we demonstrate how the latter is a therapeutic target for lowering LDL-C levels in hyperlipidemia. The medical animation goes on to explain the mechanism of action (MOA) of evolucumab, a PCSK9 inhibitor.